Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice

Journal of Neuroscience

Volumn 30, Issue 41, 2010, Pages 13707-13717

  Andrews Zwilling, Yaisa ^a,c   Bien Ly, Nga ^a   Xu, Qin ^a,b   Li, Gang ^a,c   Bernardo, Aubrey ^a   Yoon, Seo Yeon ^a   Zwilling, Daniel ^a,c   Yan, Tonya Xue ^a   Chen, Ligong ^a   Huang, Yadong ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; PENTOBARBITAL; PICROTOXIN; TAU PROTEIN; 4 AMINOBUTYRIC ACID;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; GABAERGIC SYSTEM; GROUPS BY AGE; IMMUNOHISTOCHEMISTRY; INTERNEURON; LEARNING DISORDER; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAUOPATHY; AGE; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; DRUG EFFECTS; ELECTROPHYSIOLOGY; GENETICS; MAZE TEST; MEMORY DISORDER; METABOLISM; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTOSOME; TRANSGENIC MOUSE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; APOLIPOPROTEIN E4; CELLS, CULTURED; DENTATE GYRUS; ELECTROPHYSIOLOGY; FEMALE; GAMMA-AMINOBUTYRIC ACID; IMMUNOHISTOCHEMISTRY; INTERNEURONS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; PENTOBARBITAL; PRESYNAPTIC TERMINALS; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 77958023983     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4040-10.2010     Document Type: Article

References (65)

1. Bareggi SR, Franceschi M, Bonini L, Zecca L, Smirne S (1982) Decreased CSF concentrations of homovanillic acid and γ-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications? Arch Neurol 39:709-712.
2. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118:103-113.
3. Bour A, Grootendorst J, Vogel E, Kelche C, Dodart J-C, Bales K, Moreau P-H, Sullivan PM, Mathis C (2008) Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res 193:174-182.
4. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu G-Q, Xu Q, Fish JD, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y (2004) Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24:2527-2534.
5. Brosh I, Barkai E (2009) Learning-induced enhancement of feedback inhibitory synaptic transmission. Learn Mem 16:413-416.
6. Brunden KR, Trojanowski JQ, Lee VMY (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-793.
7. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333-344.
8. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DE, Snyder CH, Alexander GE, Rademakers R, Reiman EM (2009) Longitudinal modeling of age-related memory decline and the APOE ε4 effect. N Engl J Med 361:255-263.
9. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
10. Crowther RA (1993) Tau protein and paired helical filaments of Alzheimer's disease. Curr Opin Struct Biol 3:202-206.
11. Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ (2008) Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135:549-560.
12. Davies P, Katzman R, Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 288:279-280.
13. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP (2001) Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114:1179-1187.
14. Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, Welsh-Bohmer KA, Cabeza R (2010) Temporal lobe functional activity and connectivity in young adult APOE ε4 carriers. Alzheimers Dement 6:303-311.
15. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278:1349-1356.
16. Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE (2009) Distinct patterns of brain activity in young carriers of the APOE-ε4 allele. Proc Natl Acad Sci U S A 106:7209-7214.
17. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 293:1491-1495. (Pubitemid 32807681)
18. Grouselle D, Winsky-Sommerer R, David JP, Delacourte A, Dournaud P, Epelbaum J (1998) Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci Lett 255:21-24.
19. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
20. Hardy J, Cowburn R, Barton A, Reynolds G, Dodd P, Wester P, O'Carroll AM, Lofdahl E, Winblad B (1987) A disorder of cortical GABAergic innervation in Alzheimer's disease. Neurosci Lett 73:192-196. (Pubitemid 17223705)
21. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A 100:10966-10971.
22. Harris FM, Tesseur I, Brecht WJ, Xu Q, Mullendorff K, Chang S, Wyss-Coray T, Mahley RW, Huang Y (2004a) Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J Biol Chem 279:3862-3868.
23. Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y (2004b) Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J Biol Chem 279:44795-44801. (Pubitemid 39430890)
24. Hartman RE, Wozniak DF, Nardi A, Olney JW, Sartorius L, Holtzman DM (2001) Behavioral phenotyping of GFAP-apoE3 and-apoE4 transgenic mice: ApoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp Neurol 170:326-344.
25. Herz J (2009) Apolipoprotein E receptors in the nervous system. Curr Opin Lipidol 20:190-196.
26. Herz J, Beffert U (2000) Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat Rev Neurosci 1:51-58.
27. Hoe HS, Rebeck GW (2008) Functional interactions of APP with the apoE receptor family. J Neurochem 106:2263-2271.
28. Hu JH, Ma YH, Jiang J, Yang N, Duan SH, Jiang ZH, Mei ZT, Fei J, Guo LH (2004) Cognitive impairment in mice over-expressing gamma-aminobutyric acid transporter 1 (GAT1). Neuroreport 15:9-12.
29. Huang Y (2006a) Apolipoprotein E and Alzheimer disease. Neurology 66 [Suppl 1]:S79-S85.
30. Huang Y (2006b) Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. Curr Opin Drug Discov Dev 9:627-641.
31. Huang Y (2010) Aβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med 16:287-294.
32. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW (2001) Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 98:8838-8843.
33. Irizarry MC, Rebeck GW, Cheung B, Bales K, Paul SM, Holzman D, Hyman BT (2000) Modulation of Aβ deposition in APP transgenic mice by an apolipoprotein E null background. Ann N Y Acad Sci 920:171-178.
34. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142:387-397.
35. Jasinska M, Siucinska E, Cybulska-Klosowicz A, Pyza E, Furness DN, Kossut M, Glazewski S (2010) Rapid, learning-induced inhibitory synaptogenesis in murin barrel field. J Neurosci 30:1176-1184.
36. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63:287-303.
37. Lewis J, Dickson DW, Lin W-L, Chisholm L, Corral A, Jones G, Yen S-H, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
38. Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K, Halabisky B, Deng C, Mahley RW, Huang Y (2009) GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 5:634-645.
39. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240:622-630.
40. Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 103:5644-5651.
41. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541:163-166.
42. Nitz D, McNaughton B (2004) Differential modulation of CA1 and dentate gyrus interneurons during exploration of novel environments. J Neurophysiol 91:863-872.
43. Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66:435-440.
44. Perrin RJ, Fagan AM, Holtzman DM (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461:916-922.
45. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L (1998) Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci U S A 95:10914-10919.
46. Raber J, Wong D, Yu G-Q, Buttini M, Mahley RW, Pitas RE, Mucke L (2000) Apolipoprotein E and cognitive performance. Nature 404:352-354.
47. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to β-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99:6364-6369.
48. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, Mucke L (2007) Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's diseasemousemodel. Science 316:750-754.
49. Seidl R, Cairns N, Singewald N, Kaehler ST, Lubec G (2001) Differences between GABA levels in Alzheimer's disease and Downsyndrome with Alzheimer-like neuropathology. Naunyn Schmiedebergs Arch Pharmacol 363:139-145.
50. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6:487-498.
51. Small SA, Duff K (2008) Linking Aβ and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60:534-542.
52. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977-1981.
53. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong L-M, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD (1994) Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A 91:11183-11186.
54. Sullivan PM, Mace BE, Maeda N, Schmechel DE (2004) Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 124:725-733.
55. Tanzi RE, Bertram L (2001) New frontiers in Alzheimer's disease genetics. Neuron 32:181-184.
56. Tesseur I, Van Dorpe J, Bruynseels K, Bronfman F, Sciot R, Van Lommel A, Van Leuven F (2000a) Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am J Pathol 157:1495-1510.
57. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F (2000b) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 156:951-964.
58. Vepsäläinen S, Helisalmi S, Koivisto AM, Tapaninen T, Hiltunen M, Soininen H (2007) Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients. J Neurol 254:1504-1508.
59. Weisgraber KH (1994) Apolipoprotein E: structure-function relationships. Adv Protein Chem 45:249-302.
60. Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238.
61. Xu Q, Walker D, Bernardo A, Brodbeck J, Balestra ME, Huang Y (2008) Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. J Neurosci 28:1452-1459.
62. Xue S, Jia L, Jia J (2009) Association between somatostatin gene polymorphisms and sporadic Alzheimer's disease in Chinese population. Neurosci Lett 465:181-183.
63. Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult neurogenesis. Cell 132:645-660.
64. Zhong N, Weisgraber KH (2009) Understanding the association of apolipoprotein E4 with Alzheimer's disease: clues from its structure. J Biol Chem 284:6027-6031.
65. Zimmer R, Teelken AW, Trieling WB, Weber W, Weihmayr T, Lauter H (1984) γ-Aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer's type. Arch Neurol 41:602-604.